- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00583895
Safety and Efficacy Study of ImCOOH Cream in Patients Suffering From Moderate Atopic Dermatitis
Phase IIa, Randomized, Double-blind, Placebo-controlled, Intra-individual Left-right Limb Comparison Trial in 25 Patients With Moderate Atopic Dermatitis to Investigate the Efficacy, Local Irritation, Safety, Tolerability and Pharmacokinetics of Twice Daily Topical Applications With 10% ImCOOH Cream for 14 Days With an Additional Morning Application on Day 15.
연구 개요
상세 설명
This is a Phase IIa, randomized, double-blind, placebo-controlled, intra-individual left-right limb comparison trial to investigate the efficacy, local irritation, safety, tolerability and pharmacokinetics of multiple topical applications of ImCOOH cream. The trial population will consist of 25 patients with moderate atopic dermatitis. Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15. Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15. The creams will be applied on 2 comparative target areas (minimum 0.1% and maximum 2% of the total body surface area per target area), with one site at the left limb and one site at the right limb. The applied creams needs to be prevented from wiping off. Efficacy will be assessed until Day 15 and safety and tolerability will be monitored until 14 days after the last application.
Efficacy will be assessed by determining the Topical Atopic Dermatitis Severity Index (toADSI) score, and the Visual Analogue Scale for Pruritis (VAS) score for both target areas at screening, predose on Day 1 of treatment and on Days 2, 7, 9, 12 and 15 of treatment. In addition, color pictures of the target areas will be taken predose on Day 1 of treatment and on Days 7 and 15 of treatment. Finally the Eczema Area and Severity Index (EASI) score will be determined for both target areas, predose on Day 1 of treatment and on Days 7 and 15 of treatment.
Safety will be assessed by monitoring (S)AEs, performing clinical laboratory tests (hematology, biochemistry, urinalysis) and physical exams and by taking vital signs and recording ECGs on a regular basis.
For pharmacokinetic analysis, plasma concentrations of ImCOOH will be determined on Days 1 and 15 up to 12 hours postdose. In addition, the morning predose plasma concentration of ImCOOH will be determined on Days 2, 4, 7, 9, and 12. Full urinary output will be collected on Day 15 up to 12 hours postdose to determine the amount of unchanged ImCOOH excreted in urine. In the patients who received the placebo cream only, the endogenous ImCOOH concentrations in plasma and urine will be measured.
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Malaga
-
Torremolinos, Malaga, 스페인, 29620
- InPEC B.V. (Clinical Research Unit)
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female aged between 18 and 70 years, extremes included.
- Skin type I, II, III, or IV.
- Able to comply with protocol requirements.
- Informed Consent Form (ICF) signed voluntarily before the first trial-related activity.
- Nonsmoking or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to selection.
- Normal weight as defined by a Quetelet Index (Body Mass Index [BMI]: weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2, extremes included.
- Patients having atopic dermatitis according to the integrated list with criteria for atopic dermatitis.
- Comparative target areas: minimum 0.1% and maximum 2% of the total body surface area per target area with one site at the left limb and one site at the right limb. Both target areas should be located at the arms (armpits [axillas] are also allowed) or both target areas should be located at the hollows of the knee.
- Topical Atopic Dermatitis Severity Index (toADSI) score of at least 5 for both target areas and the severity of the 2 sites do not differ by more than 3 points.
- General medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial.
Exclusion Criteria:
Female subject of childbearing potential without use of effective birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period;
Note: Estrogen based hormonal contraception may not be reliable when ImCOOH cream is applied, therefore to be eligible for this trial, women of childbearing potential should either:
- use a double barrier method to prevent pregnancy (i.e., using a condom with either diaphragm or cervical cap);
- use hormonal based contraceptives in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom);
- use an intrauterine device in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom);
- be only non-heterosexually active, practice heterosexual abstinence, or have a vasectomized partner (confirmed sterile).
Women with tubal ligation are required to use 1 non-hormonal contraceptive method.
Women who are postmenopausal for at least 2 years, and women with total hysterectomy are considered of non-childbearing potential.
- A positive pregnancy test or breast feeding at screening.
- A positive HIV-1 or -2 test at trial screening.
- Hepatitis B infection (confirmed by hepatitis B surface antigen) or hepatitis C infection (confirmed by hepatitis C virus antibody) at trial screening.
- Having a target area that is hairy in such extent that in the investigator's opinion it could influence the application.
- Having a target area that is tattooed.
- Unable to take venous blood samples for pharmacokinetics (PK) outside the elbow fold (fossa cubitus) area in case both elbow folds are part of the target areas.
- Patients receiving radiation therapy, systemic therapy with cytostatics or immunosuppressive drugs within 24 weeks before the first application of trial medication.
- Patients receiving phototherapy or systemic therapy for atopic dermatitis within 4 weeks before the first application of trial medication.
- Patients receiving antibiotics or topical therapy for atopic dermatitis within 2 weeks before the first application of trial medication. However, once-daily use of 1% hydrocortisone acetate is allowed on all lesions with the exception of the test sites and emollients are allowed to be used liberally but not on the test sites.
- Patients taking antihistamines within 1 week before the first application of trial medication.
- Patients with any acute skin infection (superinfection or secondary impetiginisation).
- Any condition (including but not limited to alcohol and drug use), which in the opinion of the investigator could compromise the patient safety or compliance with trial procedures.
- Any history or currently active allergy such as but not limited to drug allergy, food allergy or hay fever.
- Previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the trial medication administered in this trial.
- Participation in an investigational drug trial within 30 days prior to the first application of trial medication.
- Donation of blood or plasma in the 60 days preceding the first application of trial medication.
Patients with the following laboratory abnormalities at screening:
- serum creatinine > 1.1 x ULN;
- hemoglobin ≤ 10.9 g/dL;
- platelet count grade ≤ 125 x 109/L;
- absolute neutrophil count ≤ 1.3 x 109/L;
- aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 1.25 x ULN;
- total bilirubin ≥ 1.1 x ULN;
- proteinuria or hematuria;
- any other moderate or severe laboratory abnormality.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: 1
Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
|
Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
|
위약 비교기: 2
Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
|
Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Topical Atopic Dermatitis Severity Index (toADSI) score
기간: screening, predose on Day 1 and on Day 2, 7, 9 and 15
|
screening, predose on Day 1 and on Day 2, 7, 9 and 15
|
Visual Analogue Scale for Pruritis (VAS) score
기간: Screening, Day 1 predose, Day 2, 7, 9, 12 and 15
|
Screening, Day 1 predose, Day 2, 7, 9, 12 and 15
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Eczema Area and Severity Index (EASI) score
기간: Day 1 predose, Day 7 and 15
|
Day 1 predose, Day 7 and 15
|
ImCOOH plasma and urine concentrations
기간: Day 1 and 15 (plasma) up to 12 hours postdose and predose on Day 2, 4, 7, 9 and 12. Day 15(urine) up to 12 hours postdose
|
Day 1 and 15 (plasma) up to 12 hours postdose and predose on Day 2, 4, 7, 9 and 12. Day 15(urine) up to 12 hours postdose
|
공동 작업자 및 조사자
수사관
- 연구 의자: Jan D Bos, M.D., Ph.D, FRCP, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
10% ImCOOH cream에 대한 임상 시험
-
University of NottinghamNational Institute for Health Research, United Kingdom완전한
-
Celularity Incorporated완전한
-
Merry, Graham, M.D.완전한
-
Armata Pharmaceuticals, Inc.Walter Reed Army Institute of Research (WRAIR)완전한
-
Medical College of WisconsinThe New York Eye & Ear Infirmary완전한